News in English
-
PostNews: Press Release
PHI Enters Biomanufacturing Partnership with Wake Forest Institute for Regenerative Medicine
PHI and Wake Forest Institute for Regenerative Medicine recently signed a letter of intent outlining a biomanufacturing initiative to make indispensable imaging techniques available for regenerative medicine and large-scale production of cell therapies and organs.
-
PostNews: Press Release
PHI Signs Subscription Commitments with Board Members, CEO and Owners
Subscription commitments corresponding to approximately 4 % of the initial rights issue (2.9 million SEK) have been signed with members of the company’s board, the company’s CEO and with owners.
-
PostNews: Press Release
BioStock: PHIs CEO eyes new business opportunities
BioStock contacted CEO Peter Egelberg to find out more about the rights issue of just over 72 million SEK that is currently underway, and his vision for the future.
-
PostNews: Press Release
HoloMonitor Fluorescence Now at Novo Nordisk
PHI recently installed a fluorescence-equipped HoloMonitor® system at Novo Nordisk A/S. The installation is part of a series of test installations to allow experienced HoloMonitor customers to provide feedback regarding functionality and user-friendliness prior to the upcoming product launch.
-
PostNews: Press Release
PHI changes the date for publication of Interim Report 3 2021/22
The reason for the change of date is to allow management and staff to participate in the newly decided rights issue by purchasing shares.
-
PostNews: Press Release
Continued Sales Growth for PHI
PHI’s sales in November – January gained 240 % and amounted to 2.7 (0.8) MSEK. Sales over the past four fiscal quarters (Feb 2021 – Jan 2022) amount to 8.8 (2.3) MSEK.
